jobs.jnj.com/en/jobs/
Skip to content
✕
Internet Explorer is no longer supported by this website.
For optimal browsing we recommend using
Chrome
,
Firefox
or
Safari
.
Home Link (JNJ Logo)
Home Link (JNJ Logo)
Home Link (JNJ Logo)
Home Link (JNJ Logo)
Menu
Menu
Toggle Menu
Change Country
Our Businesses
Our Stories
Latest News
Innovation
Caring & Giving
Personal Stories
Health & Wellness
Our Heritage
Our Company
About J&J
Our Credo
Our Leadership Team
Code of Business Conduct
Corporate Reports
Diversity, Equity & Inclusion
ESG Policies & Positions
Innovation at J&J
Digital Solutions
J&J Health and Wellness Solutions
Office of the Chief Medical Officer
Veterans, Military & Military Families
Products
MedTech
Pharmaceutical Products
Suppliers
Responsible Supply Base
Supplier-Enabled Innovation
Supplier Resources
Careers
Life at J&J
Diversity, Equity and Inclusion
Career Areas of Impact
Students
Re-Ignite Program
Contract & Freelance Partner Opportunities
Career Stories
Media Center
Investors
2023 Annual Meeting of Shareholders
Corporate Governance
Quarterly Results
SEC Filings
News Releases
Pharmaceutical Pipeline
2022 Janssen Transparency Report
2022 Health for Humanity Report
ESG Resources
Stock Information
Webcasts & Presentations
Investor Fact Sheet
Our Societal Impact
Global Community Impact
Global Public Health
Global Environmental Sustainability
Close Countries Menu
Explore more Johnson & Johnson sites:
China
France
Germany
India
Japan
Russia
Switzerland
German
English
French
United Kingdom
United States
Search input
Dictate search request
Empty search box
Recently Viewed
Share
Global Public Health
News & Press Releases
Media Statement
November 15, 2022
Johnson & Johnson Rises to #2 in Ranking of Companies’ Efforts to Expand Access to Medicines Worldwide
Global Public Health
June 20, 2022
Johnson & Johnson Opens First Satellite Center for Global Health Discovery in Asia Pacific at Duke-NUS to Advance Dengue Research
Global Public Health
May 23, 2022
New Global Surgery Initiative Aims to Improve Access to Quality Surgical Care in Resource-Limited Settings
MEDIA STATEMENT
January 27, 2022
Johnson & Johnson Marks More Than 2 Billion Doses of Medicine Donated to Date to Help Combat Intestinal Worms
Global Public Health
November 18, 2021
Johnson & Johnson is Proud to Lead Efforts to Outpace Antimicrobial Resistance
Innovation
The Sky's the Limit: Drones Delivering HIV Supplies in Remote Uganda
Innovation
July 22, 2021
How Drones Are Being Used to Deliver Lifesaving HIV Drugs to Remote Areas of the World
Personal Stories
July 19, 2021
"1.5 Million Children Are Living With HIV in Sub-Saharan Africa. I'm One of the Doctors Treating These Young Patients Every Day"
Innovation
How the New Horizons Collaborative is Transforming Pediatric HIV in Uganda
Our Company
July 09, 2021
Johnson & Johnson Launches Network of Global Health Discovery Centers that Aim to Speed Up Science and Tackle Pandemic Threats
Innovation
October 01, 2020
Q&A: The need for flexibility and innovation in TB care — now more than ever
Latest News
September 30, 2020
Johnson & Johnson Joins Other Companies in Signing a Landmark Communiqué on Expanded Global Access for COVID-19
Our Company
September 23, 2020
Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen’s COVID-19 Vaccine Candidate
Our Company
July 30, 2020
Single Dose of Johnson & Johnson COVID-19 Vaccine Candidate Demonstrates Robust Protection in Pre-clinical Studies
Innovation
June 17, 2020
Opinion: Why global health security is every company's business
Latest News
July 07, 2020
Johnson & Johnson and Its Partners Mark a Milestone in the Quest for a Global Preventive HIV Vaccine With the Imbokodo Study
Our Company
June 10, 2020
Johnson & Johnson Announces Acceleration of its COVID-19 Vaccine Candidate; Phase 1/2a Clinical Trial to Begin in Second Half of July
Our Company
April 24, 2020
Statement of Support on Access to New COVID-19 Tools
Our Company
March 30, 2020
Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19; Landmark New Partnership with U.S. Department of Health & Human Services; and Commitment to Supply One Billion Vaccines Worldwide for Emergency Pandemic Use
Our Company
October 08, 2020
How Rwanda is Spearheading Efforts to Tackle Mental Health
Innovation
July 06, 2020
Stop TB Partnership and Johnson & Johnson, with support from USAID and The Global Fund, Announce Price Reduction for SIRTURO
®
(bedaquiline) for Treatment of Drug-Resistant Tuberculosis in Low- and Middle-Income Countries
Innovation
July 01, 2020
Johnson & Johnson Announces European Commission Approval for Janssen’s Preventive Ebola Vaccine
Innovation
May 27, 2020
U.S. FDA Approves New Pediatric Formulation of SIRTURO
®
(bedaquiline) as Part of Combination Therapy to Treat Children with Pulmonary Multidrug-Resistant Tuberculosis
Innovation
May 27, 2020
Drug-Resistant Tuberculosis Lifeline QuickFire Challenge
Innovation
April 23, 2020
Global Advocacy and Communications Effort Launched to Drive Action Against COVID-19 and Stop Future Pandemics
Our Company
March 24, 2020
Statement on the Occasion of World Tuberculosis Day
Innovation
March 20, 2020
Janssen Announces Health Canada Approval of CABENUVA™, the First Long-Acting Regimen for the Treatment of HIV
Innovation
March 11, 2020
Janssen Announces Results of Phase 3 Study Demonstrating the Safety and Efficacy of Long-Acting Injectable HIV Treatment Regimen of Rilpivirine And Cabotegravir through 96 Weeks
Innovation
February 18, 2020
Johnson & Johnson to Expand Partnership with U.S. Department of Health & Human Services to Accelerate the Discovery of Potential COVID-19 Treatments
Innovation
February 11, 2020
Johnson & Johnson Announces Collaboration with U.S. Department of Health & Human Services to Accelerate Development of a Potential Novel Coronavirus Vaccine
Our Company
January 29, 2020
Johnson & Johnson Launches Multi-Pronged Response to Coronavirus Global Public Health Threat
Our Company
January 23, 2020
Johnson & Johnson Recognized as Industry Leader in New AMR Benchmark
Innovation
January 16, 2020
Johnson & Johnson Collaborates with The MTV Staying Alive Foundation to Launch Youth-Focused “Edutainment” Campaign Focused on Tuberculosis & Other Health Issues in India
Innovation
December 16, 2019
World Health Organization Recommends the Use of Bedaquiline-Containing Treatment Regimens For All Drug-Resistant Tuberculosis Patients
Our Company
December 08, 2019
Johnson & Johnson Announces Commitment to Support Republic of Rwanda’s Preparedness Against Ebola Outbreak
Innovation
November 07, 2019
Johnson & Johnson Announces Submission of European Marketing Authorisation Applications for Janssen’s Investigational Ebola Vaccine Regimen
Innovation
October 31, 2019
Johnson & Johnson Announces Donation of up to 500,000 Regimens of Janssen’s Investigational Ebola Vaccine to Support Outbreak Response in Democratic Republic of the Congo (DRC)
Global Public Health
October 30, 2019
Johnson & Johnson Expands Efforts to Help End Tuberculosis in India
Our Company
October 04, 2019
Johnson & Johnson Commits $500 Million Investment Over Four Years to Help End the Epidemics of HIV and Tuberculosis
Innovation
September 04, 2019
Johnson & Johnson Expands First-of-its-Kind Pediatric HIV Program to Zimbabwe
Innovation
August 22, 2019
Janssen Reports Positive Top-line Phase 3 Study Results of Investigational, Long-acting Injectable HIV Treatment Regimen Administered Every Two Months
Innovation
July 16, 2019
Johnson & Johnson Extends Long-Standing Donation Program to Support Global Effort to Tackle Intestinal Worms
Innovation
April 29, 2019
Janssen Announces Submission of New Drug Application to U.S. FDA For the First Monthly, Injectable, Two-Drug Regimen of Rilpivirine and Cabotegravir for Treatment of HIV
Innovation
September 24, 2018
Johnson & Johnson Announces 10-year Initiative to Help End Tuberculosis, the World’s #1 Infectious Killer
Innovation
August 07, 2018
Johnson & Johnson Announces Series of Collaborations Aimed at Transforming Mental Health Care in Low-Resource Settings
Learn how we're tackling the world's toughest health challenges
Learn more
Back to top
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Continue